ImmunoGen, Inc.

2020 Q4 Form 10-Q Financial Statement

#000155837020013027 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $293.9M $188.2M $176.2M
YoY Change 66.78% -7.96% -32.8%
Cash & Equivalents $293.9M $188.2M $176.2M
Short-Term Investments $0.00 $0.00 $0.00
Other Short-Term Assets $7.900M $7.900M $5.400M
YoY Change 46.3% 58.0% 20.0%
Inventory
Prepaid Expenses
Receivables $0.00 $5.100M $12.10M
Other Receivables $22.50M $18.10M $15.10M
Total Short-Term Assets $324.3M $219.3M $208.9M
YoY Change 55.22% -2.82% -25.07%
LONG-TERM ASSETS
Property, Plant & Equipment $5.760M $5.578M $6.993M
YoY Change -17.63% -38.82% -45.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.99M $8.570M $3.784M
YoY Change 190.33% 151.1% 2.02%
Total Long-Term Assets $30.82M $28.63M $26.36M
YoY Change 16.89% 0.6% 58.82%
TOTAL ASSETS
Total Short-Term Assets $324.3M $219.3M $208.9M
Total Long-Term Assets $30.82M $28.63M $26.36M
Total Assets $355.1M $248.0M $235.3M
YoY Change 50.93% -2.43% -20.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.538M $8.913M $9.933M
YoY Change -3.98% 23.33% -12.6%
Accrued Expenses $37.10M $28.20M $25.90M
YoY Change 43.24% -6.31% -19.81%
Deferred Revenue $29.25M $3.985M $309.0K
YoY Change 9365.7% -73.11% -2.52%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.100M $2.100M
YoY Change
Total Short-Term Liabilities $122.3M $99.82M $77.41M
YoY Change 58.02% 13.21% 9.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.100M
YoY Change -100.0% -100.0% 0.0%
Other Long-Term Liabilities $2.586M $2.818M $707.0K
YoY Change 265.77% 190.52% -83.09%
Total Long-Term Liabilities $2.586M $2.818M $707.0K
YoY Change 265.77% 190.52% -83.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $122.3M $99.82M $77.41M
Total Long-Term Liabilities $2.586M $2.818M $707.0K
Total Liabilities $265.5M $290.8M $311.4M
YoY Change -14.73% -14.55% 9.48%
SHAREHOLDERS EQUITY
Retained Earnings -$1.332B -$1.400B -$1.287B
YoY Change 3.45% 7.69% 8.8%
Common Stock $1.421B $1.320B $1.211B
YoY Change 17.34% 9.48% 1.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $89.57M -$42.89M -$76.12M
YoY Change
Total Liabilities & Shareholders Equity $355.1M $248.0M $235.3M
YoY Change 50.93% -2.43% -20.35%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0000855654
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
174585000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150136000
CY2019Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-17999
dei Entity Registrant Name
EntityRegistrantName
ImmunoGen, Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-2726691
dei Entity Address Address Line1
EntityAddressAddressLine1
830 Winter Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
895-0600
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
IMGN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
187527748
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188217000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176225000
CY2020Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5050000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7500000
CY2020Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
5000
CY2019Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
1001000
CY2019Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
3631000
CY2020Q3 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
18180000
CY2019Q4 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
15116000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7875000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5425000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
219327000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
208898000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5578000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6993000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14477000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15587000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8570000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3784000
CY2020Q3 us-gaap Assets
Assets
247952000
CY2019Q4 us-gaap Assets
Assets
235262000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8913000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9933000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3942000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8991000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21114000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13932000
CY2020Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
11000
CY2020Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2089000
imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
402000
CY2019 imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
635000
CY2020Q3 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
56603000
CY2019Q4 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
41274000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3175000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2971000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3985000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
309000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
99821000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
77410000
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
126541000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
127123000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19403000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21798000
CY2020Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.045
CY2019Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.045
CY2019Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
22000
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
2078000
CY2020Q3 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
625000
CY2019Q4 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
859000
CY2020Q3 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
42260000
CY2019Q4 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
82267000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2818000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
707000
CY2020Q3 us-gaap Liabilities
Liabilities
290843000
CY2019Q4 us-gaap Liabilities
Liabilities
311383000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
174585000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150136000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1746000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1501000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1318591000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1209846000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1363228000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1287468000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-42891000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-76121000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
247952000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235262000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
18189000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13281000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
46501000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
37407000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24685000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21015000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
75014000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88467000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10231000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9208000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28862000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28686000
CY2019Q3 us-gaap Restructuring Charges
RestructuringCharges
1020000
us-gaap Restructuring Charges
RestructuringCharges
1524000
us-gaap Restructuring Charges
RestructuringCharges
20921000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
34916000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
31243000
us-gaap Operating Expenses
OperatingExpenses
105400000
us-gaap Operating Expenses
OperatingExpenses
138074000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16727000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17962000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58899000
us-gaap Operating Income Loss
OperatingIncomeLoss
-100667000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
11000
CY2019Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1032000
us-gaap Investment Income Net
InvestmentIncomeNet
719000
us-gaap Investment Income Net
InvestmentIncomeNet
3741000
CY2020Q3 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
5645000
CY2019Q3 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
4275000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
17428000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
11525000
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
24000
CY2019Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
24000
us-gaap Interest Expense Debt
InterestExpenseDebt
71000
us-gaap Interest Expense Debt
InterestExpenseDebt
71000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-521000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-81000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-425000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-22374000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-21750000
us-gaap Net Income Loss
NetIncomeLoss
-75760000
us-gaap Net Income Loss
NetIncomeLoss
-108947000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
174508000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
148479000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
172215000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
148143000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22374000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5007000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21750000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75760000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108947000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10972000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-43751000
CY2019Q1 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
68000
CY2019Q1 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
100000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-27604000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-43446000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
670000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2106000
CY2019Q2 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
100000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-68174000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-21750000
CY2019Q3 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
73000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3580000
CY2019Q3 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
46000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-86225000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
4814000
CY2019Q4 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
2061000
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3138000
CY2019Q4 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
91000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-76121000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-29088000
CY2020Q1 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
240000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
97744000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3122000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4103000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-24298000
CY2020Q2 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
425000
CY2020Q2 imgn Adjustment Related To Issuance Costs
AdjustmentRelatedToIssuanceCosts
-1000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3409000
CY2020Q2 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
45000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-24523000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-22374000
CY2020Q3 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
128000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3729000
CY2020Q3 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
149000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-42891000
us-gaap Profit Loss
ProfitLoss
-75760000
us-gaap Profit Loss
ProfitLoss
-108947000
imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
45159000
imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
32102000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
17428000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
11525000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1569000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3277000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
691000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2544000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
694000
us-gaap Share Based Compensation
ShareBasedCompensation
10454000
us-gaap Share Based Compensation
ShareBasedCompensation
10939000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2450000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1607000
imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
-996000
imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
2392000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-3631000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2450000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
499000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2762000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
793000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
811000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
230000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97743000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
98536000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
811000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
11992000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-57761000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176225000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262252000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3094000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
65050000
imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-2191000
imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-1823000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-87155000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55810000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
815000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2762000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
1426000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
611000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188217000
imgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1110000
imgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
994000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4786000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-296000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1028000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3751000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4651000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2336000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
8829000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-6058000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
204491000
us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Nature of Business and Plan of Operations</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development of antibody-drug conjugates, or ADCs. The Company has generally incurred operating losses and negative cash flows from operations since inception, incurred a net loss of $75.8 million during the nine months ended September 30, 2020, and has an accumulated deficit of approximately $1.4 billion as of September 30, 2020. The Company has primarily funded these losses through payments received from its collaborations and equity, convertible debt, and other financings. To date, the Company has no product revenue and management expects operating losses to continue for the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">At September 30, 2020, the Company had $188.2 million of cash and cash equivalents on hand. The Company anticipates that its current capital resources, inclusive of approximately $54.0 million of net proceeds generated from an Open Market Sale Agreement<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> in October 2020, and anticipated payments from collaborators, including a $40.0 million upfront license payment from a newly executed agreement detailed in Note B below, will enable it to meet its operational expenses and capital expenditures for more than twelve months after the date these financial statements are issued. The Company may raise additional funds through equity, debt, or other financings, or generate revenues from collaborators through a combination of upfront license payments, milestone payments, royalty payments, and research funding. There can be no assurance that the Company will be able to obtain additional equity, debt, or other financing or generate revenues from collaborators on terms acceptable to the Company or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition and require the Company to defer or limit some or all of its research, development, and/or clinical projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, complexities associated with managing collaboration arrangements, third-party reimbursements, and compliance with governmental regulations.</p>
us-gaap Profit Loss
ProfitLoss
-75800000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1400000000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188200000
imgn Current Capital Resources To Meet Operational Expenses And Capital Expenditures Expected Period
CurrentCapitalResourcesToMeetOperationalExpensesAndCapitalExpendituresExpectedPeriod
P12M
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
130500000
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.03
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.86
CY2020Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.11
CY2019Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
3631000
us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
8000000
CY2020Q3 imgn Contract Asset Impact Of Netting
ContractAssetImpactOfNetting
4369000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
127432000
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
50000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
1325000
CY2020Q3 imgn Contract Liabilities Impact Of Netting
ContractLiabilitiesImpactOfNetting
4369000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
130526000
CY2018Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
500000
us-gaap Contract With Customer Asset Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerAssetIncreaseDecreaseForContractAcquiredInBusinessCombination
0
us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
500000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
80802000
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
65287000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
237000
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
145852000
CY2020Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
72000
CY2019Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
79000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1300000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
237000
CY2020Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
25000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
25000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
5000000
imgn Cash And Cash Equivalents Number Of Financial Institutions
CashAndCashEquivalentsNumberOfFinancialInstitutions
3
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
0
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188200000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176200000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
100000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
imgn Number Of Trades Impacting Fair Value Of Financial Instruments
NumberOfTradesImpactingFairValueOfFinancialInstruments
0
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2020Q3 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
19181000
CY2019Q3 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
18754000
imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
19181000
imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
18754000
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
929000
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
731000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1112000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
926000
CY2020Q3 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
CY2019Q3 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
CY2020Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
CY2019Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
imgn Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans
3
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
175000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
imgn Number Of Real Estate Leases
NumberOfRealEstateLeases
2
CY2019Q1 imgn Unamortized Lease Incentive And Straight Line Lease Liability Balances
UnamortizedLeaseIncentiveAndStraightLineLeaseLiabilityBalances
9700000
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
us-gaap Operating Lease Expense
OperatingLeaseExpense
3000000.0
us-gaap Operating Lease Expense
OperatingLeaseExpense
3300000
us-gaap Operating Lease Payments
OperatingLeasePayments
4100000
us-gaap Operating Lease Payments
OperatingLeasePayments
4000000.0
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14500000
CY2020Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
2100000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5470000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
22600000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1379000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5323000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5389000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5510000
CY2020Q3 imgn Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6866000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
29937000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7359000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
22578000
us-gaap Variable Lease Cost
VariableLeaseCost
3400000
us-gaap Sublease Income
SubleaseIncome
1600000

Files In Submission

Name View Source Status
0001558370-20-013027-index-headers.html Edgar Link pending
0001558370-20-013027-index.html Edgar Link pending
0001558370-20-013027.txt Edgar Link pending
0001558370-20-013027-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imgn-20200930.xsd Edgar Link pending
imgn-20200930x10q.htm Edgar Link pending
imgn-20200930x10q_htm.xml Edgar Link completed
imgn-20200930xex31d1.htm Edgar Link pending
imgn-20200930xex31d2.htm Edgar Link pending
imgn-20200930xex32.htm Edgar Link pending
imgn-20200930_cal.xml Edgar Link unprocessable
imgn-20200930_def.xml Edgar Link unprocessable
imgn-20200930_lab.xml Edgar Link unprocessable
imgn-20200930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending